This study sought to determine the clinical and biological significance of elevated cardiac troponin T (cTnT) in patients with neuromuscular diseases.
Troponin is a regulatory protein complex located on the thin filament of striated muscles. It consists of 3 subunits: C, I, and T. Troponins I and T have 3 isoforms, each controlled by different genes; 1 is cardiac and the other 2 are slow skeletal and fast skeletal isoforms. Cardiac troponin T (cTnT) and cardiac troponin I (cTnI) have become the biomarkers of choice for the diagnosis of acute myocardial infarction (AMI), superceding the creatine kinase myocardial band (CK-MB) (1) (2) (3) . Elevation of either marker in the circulation is generally interpreted as indicative of myocardial necrosis. The third edition of the universal definition of myocardial infarction (4) , endorsed by the European Society of Cardiology, the American Heart Association, the American College of Cardiology Foundation, and the World Heart Federation, re-emphasizes the preeminent diagnostic role of cardiac troponins and makes no distinction between cTnT and cTnI. Similarly, the recent American College of Cardiology Foundation recommendations on the interpretation of elevated cardiac troponins assume that the 2 biomarkers have equivalent diagnostic accuracy for myocardial injury (5) .
Our clinical experience with patients with neuromuscular diseases led us to question the cardiac specificity of the commercial cTnT immunoassay. We observed that these patients commonly have elevated cTnT without any clinically apparent evidence of myocardial injury. Although cTnT and cTnI are both absent in healthy adult skeletal muscle, cTnT, but not cTnI, is present in fetal skeletal muscle (6) (7) (8) (9) . When skeletal muscle is injured, it repairs itself by regeneration, a process that recapitulates embryonic myogenesis (10, 11) . Regenerating skeletal muscle thus re-expresses fetal isoforms of cTnT (12) (13) (14) (15) and also CK-MB (16) (17) (18) . In contrast, cTnI has not been shown to be expressed in skeletal muscle at any point of development (6) . One study reported the mRNA, but not the protein, of cTnI in the skeletal muscle of patients with Duchenne muscular dystrophy (DMD) (19) . It is not known whether these biological differences have any significant clinical implications. We studied the behavior of cTnT and cTnI in the circulation of patients with several different types of inherited and acquired neuromuscular diseases. We use the term "neuromuscular disease" to cover both primary myopathies and muscle diseases secondary to nerve disorders.
Methods
Patients. The study started in 2005 when we observed persistent elevation of cTnT and CK in patients with skeletal muscle diseases. The first group consisted of 25 hospitalized patients (ages 58 AE 17 years; range: 17 to 87 years) admitted urgently to Wirral University Teaching Hospital under the care of 1 cardiologist (D.R.). The hospital uses both cTnT and CK routinely for the assessment of patients suspected of having acute coronary syndromes.
Of these 25 patients, 13 had previously established diagnoses of neuromuscular diseases (3 facioscapulo humeral muscle dystrophy, 2 polymyositis, 2 motor neurone disease, 2 paroxysmal rhabdomyolysis, 1 inclusion body myositis [IBM] , 1 muscle sarcoma, 1 myotonic dystrophy [MyoD], 1 periodic hypokalemic paralysis). The other 12 patients received new diagnoses of skeletal myopathies (3 statininduced, 2 alcohol-induced, 1 inflammatory, 1 hypothyroid, 1 cocaine-induced, and 4 subclinical, presumed inflammatory) during the course of this study.
To validate the findings in the hospitalized group, we studied a second group consisting of 27 unselected ambulatory patients with different types of neuromuscular diseases under routine follow-up in either a neuromuscular (n ¼ 19) or cardiology (n ¼ 8) outpatient clinic. The clinical characteristics of these 2 groups of patients are shown in Table 1 .
All patients underwent full clinical assessment and routine blood tests consisting of full blood count, electrolytes, renal function, liver function, and thyroid function. Cardiac investigations in hospitalized patients comprised serial ECGs, echocardiograms, and when clinically indicated, cardiac catheterization studies (coronary angiography, left ventriculography, and pressure measurements). Serial measurements of serum CK, CK-MB, cTnT, cTnI, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were performed while in hospital and also after discharge to the outpatient clinic. ECG and echocardiography were also repeated in the clinic at 4 to 6 monthly intervals. Ambulatory patients had single measurements of these biomakers in addition to ECGs and echocardiograms. The study was approved by the local research ethics committee, and patients gave written informed consent. Cardiac troponin immunoassays. Roche Diagnostics (Indiana, Indianapolis) is the sole manufacturer of cTnT assays. Serum cTnT was measured initially using the standard third-and fourth-generation assays, and subsequently by the high-sensitivity (hs-cTnT) assay when it became commercially available. The standard assay has a limit of detection of 0.01 mg/l, a 99th percentile of <0.01 mg/l, and a coefficient of variation of 10% at 0.03 mg/l. The corresponding values for the hs-cTnT assay are 0.005, 0.014, and 0.013 mg/l (20) .
Serum cTnI was measured using 2 immunoassays, Siemens cTnI-Ultra (Siemens Corporation, Washington, DC) and Roche troponin I. The cTnI-Ultra assay has a limit of detection of 0.006 mg/l, a 99th percentile of 0.04 mg/l, and a 10% coefficient of variation at 0.03 mg/l. The corresponding values for the Roche I assay are 0.10, 0.16, and 0.30 mg/l, as obtained from the manufacturer's package insert.
To ascertain that the cTnI-Ultra assay is at least as sensitive as the conventional cTnT assay for the detection of relatively minor myocardial injury, serum samples with low concentrations of cTnT (median cTnT 0.14 mg/l; interquartile range 0.06 to 0.33) from 32 randomly selected patients with unequivocal AMI were analyzed. cTnI-Ultra was elevated (>0.04 mg/l) in 31 patients. One patient with cTnT of 0.03 mg/l had a cTnI-Ultra of 0.02 mg/l.
Regression analysis yielded the following relationship: cTnI-Ultra ¼ 13.32 cTnT -0.70 (r ¼ 0.89, p < 0.0001).
Serum CK-MB and NT-proBNP concentrations were measured using Roche Diagnostics immunoassays. CK was considered normal if <170 U/l in women and <200 U/l in men.
All assays were performed according to the manufacturers' instructions by experienced laboratory personnel blinded to the study. Statistical analysis. Continuous variables are reported as medians with interquartile ranges or as means with SDs.
Results
Hospitalized patients (n [ 25). 25 patients. Fifteen patients were referred with an initial diagnosis of acute coronary syndromes, of whom only 1 had acute ischemic ECG changes. The other 10 patients had no cardiac symptoms or ischemic ECG changes. ECGs and echocardiograms were normal in 15 and 17 patients, respectively. Cardiac catheterization studies were performed on 15 occasions in 10 patients, 9 of whom presented with chest pain. Cardiac catheterization was deemed to be clinically inappropriate in the other 15 patients. Coronary angiograms were normal on 12 occasions in 7 patients. Left ventriculograms and left ventricular end-diastolic pressures were normal on 13 occasions in 9 patients. After initial hospital discharge, further ECGs and echocardiograms were performed, either in the outpatient clinic or through readmission in 21 and 17 patients, respectively. No patient had new ECG or echocardiographic changes.
Despite the several different types of chronic injury to skeletal muscle in this group, the observed biochemical response was the same in almost all patients. Serial measurements before any therapeutic interventions showed persistent elevation of cTnT (0.08 mg/l; 0.04 to 0.13 mg/l), CK (500 U/l; 177 to 3,100 U/l), and CK-MB (15 mg/l; 8 to 33 mg/l). These results are the medians and interquartile ranges of the medians for each patient. In complete contrast, cTnI was below the 99th percentile or even below the detection limit in 22 patients. In 2 patients with severe left ventricular dysfunction and a history of cardiac failure, all 4 biomarkers were persistently elevated. In a third patient with mitral valve replacement and atrial fibrillation, cTnI was just above the upper reference limit, at 0.05 mg/l. In all 3 patients, the elevated cTnI was noted to be disproportionately low compared with cTnT, as shown in Table 2 . One patient with IBM was admitted with acute chest pain and ST elevation. Although the diagnosis of AMI was not in doubt, the admission values of cTnT (0.19 mg/l), cTnI (0.62 mg/l), and CK (1333 U/l) were discordant. These markers were rechecked 4 weeks later when serial cTnI was found to be persistently negative, but cTnT (mean 0.12 mg/l) and CK (mean 895 U/l) remained persistently elevated.
Two patients triggered our interest and led us to conduct this study. Over a 3-year period, patient #1 had multiple admissions with chest pain and alcohol abuse. ECGs (>70) and echocardiograms were normal. Her cTnT (0.13 mg/l; 0.06 to 0.22 mg/l) and CK (2,699 U/l; 1,457 to 5,193 U/l) were found to be elevated on 49 occasions. Her initial coronary angiogram showed a moderate stenosis in the mid left anterior descending artery. Despite stent placement, her admissions to hospital with chest pain and cTnT elevation continued. Further coronary angiography showed no obstructive disease, including a fully patent left anterior descending artery. Patient #2 also had multiple admissions with chest pain over a 7-year period. Cardiac investigations, including cardiac catheterization studies performed on 3 occasions, were normal. Her CK (314 U/l; 115 to 481 U/l) and cTnT (0.14 mg/l; 0.11 to 0.20 mg/l) were elevated on 70 occasions. In these 2 patients, cTnI measured by both assays was consistently within the normal range. The diagnosis of skeletal myopathy was established on biopsy during the course of this study, and previous diagnoses of acute coronary syndromes were revised.
The patient with hypothyroid myopathy provided us the opportunity to study the response of cTnT, cTnI, CK, and CK-MB to hormone replacement (Table 3 ). After 6 months of treatment, levo-thyroxine replacement reversed the clinical signs of myopathy and normalized cTnT, CK, and CK-MB levels. In contrast, cTnI-Ultra was normal and barely detectable throughout the study. NT-proBNP was also normal. Table 4 charts the chronological development of statininduced myopathy in patient #11 and biochemical response to treatment. Withdrawal of the drug and initiation of steroid therapy led to gradual clinical improvement and normalization of CK, CK-MB, and cTnT levels; cTnIUltra and NT-proBNP were normal.
Patient #14 demonstrated that even local chronic injury to muscledin this case, invasion of thigh muscles by a highgrade pleiomorphic sarcomadwill cause persistent release of cTnT, CK, and CK-MB, but not cTnI.
We examined the kinetics of serum cTnT in 21 patients during 34 separate hospital stays. Data was available on 138 samples taken on different days. Figure 1 illustrates the profile of serum cTnT in hospitalized patients who had at least 5 samples assayed on separate days during any 1 admission episode. The maximum percentage change in cTnT concentration from one day to the next was a median of 23% (interquartile range: 13% to 33%). The percentage change between the maximum and minimum values of cTnT during admission episodes was a median of 30% (interquartile range: 13% to 56%). Thus, for example, in patient 11, cTnT dropped maximally by 31% from 0.16 mg/l on day 1 to 0.11 mg/l on day 2. In this case, 31% was also the maximal change for the entire episode (Fig. 1) . The maximum absolute change in cTnT concentration from day to day was a median of 0.02 mg/l (interquartile range: 0.01 to 0.04 mg/l). The maximum change for the entire episode was a median of 0.03 mg/l (interquartile range: 0.02 to 0.05 mg/l). Figure 2 illustrates the wide variations of cTnT over several years.
Ten patients had diagnostic skeletal muscle biopsy performed either previously (n ¼ 5) or during the course of this study (n ¼ 5). Skeletal muscle regeneration was independently reported on histology and immunohistochemistry in 7 patients.
Serum NT-proBNP measured in 15 patients in this group (56 samples) was a median of 300 pg/ml (interquartile range: 153 to 512 pg/ml).
During the mean and maximum follow-up of 2.4 and 7 years, respectively, none of the patients with elevated cTnT but normal cTnI sustained any cardiovascular events (AMI, heart failure, or stroke). Two patients with elevated cTnI died from stroke and heart failure, respectively. Four patients died from complications of their underlying neuromuscular diseases, 1 died of alcohol abuse, and 1 died of malignancy.
Ambulatory patients (n [ 27) . This group consisted of 10 patients with Becker muscular dystrophy (BMD), 5 with limb girdle muscular dystrophy (LGMD), 5 with MyoD, 3 with IBM, 2 with myasthenia gravis (MG), 1 with DMD, and 1 with Friedreich ataxia (FA). They had no symptoms other than neuromuscular. Patients with MG and FA were used as "controls" because these diseases are not characterized by CK elevation. Table 5 shows the results of individual patients. CK (715 U/l; 249 to 1213 U/l) was elevated in 21 patients, CK-MB (18 mg/l; 11 to 28 mg/l) was elevated in 22 of 23 patients tested, and hs-cTnT (0.021 mg/l; 0.011 to 0.038 mg/l) was elevated in 18 patients (7 with BMD, 4 with
LGMD, 3 with IBM, and 4 with MD) . In contrast, cTnI was normal in all but 1 patient with BMD, who had a minor elevation. Of the 6 patients (2 with MG, 1 with DMD, 1 with LGMD, 1 with BMD, and 1 with FA) with normal CK, 5 had normal cTnT. The 2 cTnI assays gave concordant results in all patients tested. NT-proBNP (41 pg/ml; 35 to 97 pg/ml) was normal in all but 2 patients.
ECGs were normal in 15 patients, and there were minor abnormalities in 3 patients. Echocardiograms were normal in 11 of 15 patients who had the test. No patient died or sustained any cardiovascular events during a mean and maximum follow-up of 2 and 5 years, respectively. Tables 2 and 3 .
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Discussion
Our study shows that patients with neuromuscular diseases characterized by elevated CK commonly have persistent elevation of circulating cTnT and CK-MB in the absence of clinical and cTnI evidence of myocardial injury. They also have normal NT-proBNP. The totally discordant behavior of the 2 cardiac troponins contrasts sharply with the concordant pattern generally seen in patients with myocardial injury. cTnT elevation has previously been described in patients with DMD (21), polymyositis and/or dermatomyositis (22) , and IBM (23, 24) . We show, for the first time, that cTnT elevation is not limited to any specific skeletal myopathies, but that it occurs across a wide spectrum of neuromuscular diseases. Whether the injury is endocrine, metabolic, autoimmune, genetic, neurally mediated, or caused by drug toxicity or malignant invasion, the same characteristic biomarker pattern was observed. Also, it does not seem to matter whether the insult is systemic or local. These findings are in accord with the known biology of skeletal muscle, whereby regeneration, a recognized source of cTnT and CK-MB (12) (13) (14) (15) (16) (17) (18) , is a universal response to any injury. We considered elevation of cTnT in our patients to be a false positive result for myocardial injury, because it was consistently at variance with the clinical findings. This view was strengthened by the demonstration that, despite persistent release of cTnT into the circulation over several years, patients had no cardiac symptoms, and serial ECGs and echocardiograms remained unchanged. Also, no cardiovascular events occurred, except in 2 patients with elevated cTnI, and there was no adverse impact on prognosis during a mean follow-up of 2 years. Furthermore, the negative results provided independently by the 2 cTnI assays also indicated absence of myocardial injury.
Falsely elevated cTnT or cTnI results can sometimes occur because of assay interference due to pre-analytical factors (e.g., hemolysis and fibrin clots) and analytical factors due to heterophile antibodies and human anti-animal antibodies (25, 26) . It seems implausible that these interfering factors would be the cause for the positive cTnT results obtained in nearly 300 samples in 44 patients in our study. Similar false negative cTnI results can occasionally be caused by cTnI autoantibodies (27, 28 ). Because we used 2 different cTnI assays that utilize different capture and detection antibodies, it is improbable that the negative results obtained by both assays in our study would be due to circulating cTnI autoantibodies or any other interfering antibodies that might exist because of skeletal muscle injury. False positive and false negative cTn results due to interfering antibodies are rarely encountered in clinical practice, whereas the systematic discordance of cTnT and cTnI results that we describe was found to be common and predictable in patients with neuromuscular diseases. Such discordance has also been reported by others in patients with skeletal muscle diseases (21, 22, 24, 29) . It is well recognized that the results of cTnT and cTnI assays are not quantitatively commutable for a variety of reasons. Unlike the cTnT assay that has a single manufacturer, cTnI assays have several. The cTnI assays are not standardized and use different antibodies targeting different epitopes (30, 31) . After AMI, cTnT and cTnI released into the circulation exist in multiple molecular forms, including free forms, degraded fragments, and complexes with other cTn molecules (32, 33) . cTnI, in particular, undergoes posttranslational modifications, such as phosphorylation, oxidation, and proteolytic degradation. These various forms also appear to be time-dependent after an AMI (34, 35) . Nonetheless, the diagnostic accuracy of cTnT and cTnI assays in the clinical setting has not been shown to be adversely affected by these factors (36) ; hence, the recommendation in consensus documents to use either assay for the diagnosis of myocardial infarction (2, 4, 5) . If myocardial injury was present in our patients, it would be expected that the 2 cTnI assays used would be able to detect at least some of, if not all, the various forms of circulating cTnI.
We showed that the standard and high-sensitivity Roche cTnT assays gave positive results, whereas both the Siemens TnI-Ultra and Roche troponin I assays produced negative results. cTnI was below the detection limit of the Roche troponin I assay in almost all patients. These same 4 assays were compared head to head in 718 patients who had symptoms suggestive of AMI. The diagnostic accuracy of the cTnI and hs-cTnT assays were found to be equivalent, and all 3 were superior to the standard cTnT assay for the early diagnosis of AMI (37) . Similar results were found by other investigators comparing cTnI-Ultra with the standard cTnT assay (38) . We also showed that the cTnI-Ultra assay yielded concordant results with the standard cTnT assay when tested in 32 patients with AMI who had cTnT elevation of the same order of magnitude as that of the patients with neuromuscular diseases. Three patients in our study further illustrate that our results cannot be explained by lack of cTnI assay sensitivity or other analytical factors. Two patients with co-existent chronic heart failure (and chronic myocardial injury) had persistent elevation of CK, CK-MB, cTnT, cTnI, and NT-ProBNP. The third patient with IBM was admitted with an acute ST-elevation myocardial infarction. The behavior of cTnT and cTnI followed the pattern that would be expected of an acute myocardial injury superimposed on chronic skeletal muscle injury. During the acute phase, both cTnT and cTnI were elevated, but a month later, serial cTnI was normal despite the fact that the cTnT was persistently elevated and was of similar magnitude as that in the acute phase.
The first-generation cTnT assay had significant cross reactivity with skeletal troponin T, a problem that was solved in the second-generation assay with the use of 2 new cardiospecific monoclonal antibodies (39) . However, in a multicenter study led by the inventors of the assay, it was observed that even this improved assay continued to register positive results in patients with DMD, although the frequency was less than that with the first-generation assay (40) . The investigators were uncertain whether this represented subclinical myocardial injury or if the assay was cross reacting with re-expressed cTnT in diseased skeletal muscle. Two studies performed shortly afterward on skeletal muscle biopsies of patients with end-stage renal disease suggested that the assay would not detect re-expressed cTnT in diseased skeletal muscle (41, 42) . The same antibody pair has been used in subsequent generations of the assay, including a re-engineered version of the hs-cTnT assay. The latter's validation study (20) did not examine its performance in patients with skeletal muscle diseases. We are the first group to study the hs-cTnT assay in patients with neuromuscular diseases.
We believe that elevated cTnT in our patients is due to the release of re-expressed cTnT from diseased skeletal muscle into the circulation. This would explain not only the clinical findings, normal levels of cTnI and NT-proBNP, but also the close relationship between cTnT and the 2 well-established markers of persistent skeletal muscle damage, that is, CK and CK-MB. CK-MB and cTnT share similar ontogenic attributes (10, 11, 43) that likely explain their co-existence in diseased skeletal muscle. We also demonstrated that treatment of patients with reversible myopathies normalizes cTnT, CK, and CK-MB in unison.
Our findings and conclusions are supported by the recent work of Jaffe et al. (44) , who also showed that patients with skeletal muscle diseases have elevated cTnT, but normal cTnI. Furthermore, by using Western blot analysis on skeletal muscle biopsies obtained from patients with inflammatory muscle disease and fascioscapulohumeral dystrophy, they demonstrated that the capture and detection antibodies used in both the standard and hs-cTnT assays are immunoreactive against proteins of the same molecular weight as that found in cardiac muscle. No such immunoreactivity was found in healthy skeletal muscle. Thus, their study confirmed that the Roche cTnT assays would give positive results whether cTnT is from the heart or skeletal muscle.
One important clinical question is whether the cTnT assay can be used to diagnose or exclude AMI in patients with neuromuscular diseases, especially those presenting with chest pain and nondiagnostic ECGs. The various criteria (relative and absolute changes in cTn) proposed (45) to distinguish acute from chronic myocardial injury may not be applicable to patients releasing cTnT from a noncardiac source. Any metrics used in patients with neuromuscular diseases will need to take account of not only analytical variation, but also the pathobiological variation of cTnT released from diseased skeletal muscle, which, in turn, will also depend on the various etiologies. We have shown that although cTnT is persistently elevated in these patients, the day to day variation can be substantial in some patients. In half of the episodes analyzed, the percentage and absolute daily changes of cTnT exceeded 20% and 20 ng/l, respectively. Further studies are required to determine whether sampling at shorter intervals (e.g., 2 to 6 hours), as opposed to our daily measurements, will help to differentiate acute myocardial injury from the chronic release of cTnT from diseased skeletal muscle. An added consideration is that small cTn changes do not necessarily rule out AMI, and conversely, a relative change of hs-cTnT of >20% appears to be common in hospitalized patients without AMI (46, 47) .
The lack of cardiac specificity of cTnT could be a possible explanation for the diagnostic and prognostic differences between cTnT and cTnI reported recently (48-51). Omland et al. (48) found hs-cTnT to be abnormally elevated in 10.9% of patients, but hs-cTnI was elevated in only 2.9% of 3,623 patients with stable coronary artery disease and preserved left ventricular systolic function. Their correlation was moderate (r ¼ 0.44), and hs-cTnI, but not hs-cTnT, was significantly and independently associated with both previous AMI and the incidence of subsequent AMI. Cullen et al. (49) evaluated hs-cTnT and hs-cTnI assays in 1,571 patients admitted to the emergency department with chest pain. Both assays had equivalent (94% vs. 96%) sensitivities for AMI, but the specificity of hs-cTnT was significantly lower (79% vs. 93%). Ungerer et al. (50) examined the performance of 3 contemporary cTnI assays (including cTnI-Ultra) and the cTnT assays in 1,773 patients using 2,358 sample pairs. Compared with each other, the cTnI assays gave discordant results in 3% to 4% of cases. In contrast, the cTnT assay produced positive results compared with negative results by the 3 cTnI assays in 14% to 16% of the samples analyzed. The TIMI (Thrombolysis In Myocardial Infarction) Study Group compared a hs-cTnI assay with the fourth-generation cTnT assay in 4,215 patients with non-ST-elevation myocardial infarction (51). The 2 assays gave concordant results in 86% of patients. Interestingly, the less sensitive cTnT assay gave positive results, whereas the hs-cTnI assay was negative in 11.5% of patients. These patients also had a low (2.1%) risk of 30-day cardiovascular death or myocardial infarction compared with 9.2% in hs-cTnI positive patients. One study that compared hs-cTnT and 2 hs-cTnI assays in patients with acute chest pain suggested that hs-cTnT is superior to hs-cTnI at predicting long-term mortality (52) . Study limitations. We have argued that elevation of circulating cTnT in patients with neuromuscular diseases originates from diseased skeletal muscle because it is a known source for it, and clinical and biochemical testing with cTnI and NT-proBNP showed no evidence of myocardial injury or stress. Skeletal muscle biopsies in our study were done for diagnostic purposes only. We made no attempt to try and identify cTnT expression in biopsy specimens. As indicated, such a study has now been performed by Jaffe et al. (44) .
The concentration of elevated hs-cTnT was relatively low (<30 ng/l) in some of our patients. Although most of them had normal ECGs, echocardiograms, and NT-proBNP levels, it might have been preferable to use a hs-cTnI assay to exclude myocardial injury in this group of patients. The chronic release of low levels of cTn from the myocardium, however, is associated with major structural heart diseases, such as dilated and hypertrophic cardiomyopathies and infiltrative diseases of the myocardium. These patients almost invariably have markedly abnormal ECGs, echocardiograms, and NT-proBNP.
Our study was not designed to answer the question of how frequently cTnT from diseased skeletal muscle could confound the diagnosis of myocardial injury in patients attending the emergency department with suspected acute coronary syndromes. Nonetheless, we believe that the number of patients affected is likely to be significant. We have shown that cTnT elevation occurs in skeletal muscle diseases of diverse etiologies. In addition to patients with well-known neuromuscular diseases, there are large numbers of individuals who are taking statins or abuse alcohol and recreational drugs. Furthermore, some patients have subclinical skeletal muscle diseases, which we diagnosed only through routine CK testing. Also, the use of the hs-cTnT assay will identify additional patients with low levels of cTnT from skeletal muscle that would not have been detected by the standard assay. One study of the causes of cTnT elevation in patients admitted to a secondary care hospital found an association with neuromuscular diseases in 6.3% (53) . Lin et al. found cTnI to be negative and CK-MB positive in 8.8% of 1,719 patients with suspected myocardial infarction, which was ascribed to skeletal muscle diseases (54) .
Conclusions
The biological differences in tissue expression between cTnT and cTnI have important clinical implications. Patients with neuromuscular diseases of diverse etiologies commonly have persistent elevation of cTnT and CK-MB without clinical or cTnI evidence of myocardial injury. The cTnT detected by the commercial assay in the circulation of these patients likely represents re-expressed cTnT released from diseased skeletal muscle. Further studies are required to determine the impact of these new findings on the diagnosis of myocardial infarction in unselected patients presenting to the emergency department with symptoms suggestive of acute coronary syndromes.
